BFS technology helps massive production of vaccine packaging in ApiJect Gigafactory
ApiJect Systems, Corp., a public benefit corporation, has been approved by the U.S. International Development Finance Corporation (DFC) for a US$590 million loan to construct a multi-facility campus enabling the U.S. to more quickly package high volumes of injectable medicines and vaccines in the event of a national emergency, beginning with COVID-19.
Located in Research Triangle Park, North Carolina, a one million sq ft campus will be home to the ApiJect Gigafactory, featuring the world’s largest pharmaceutical fill-finish facility, capable of producing annually up to 3 billion single-dose prefilled injectors.
This new facility brings together the well-established aseptic drug packaging technology known as Blow-Fill-Seal (BFS) with ApiJect’s proprietary pen needle-style hubs to package drugs reliably and safely in BFS prefilled injectors.
BFS uses pharmaceutical-grade plastic resin to create, fill and seal a strip of 12-25 drug containers per production line every three seconds in a single, highly efficient process.
